Friday, July 10, 2026

Drug profile · INN

mexiletine hcl

mexiletine hcl (NAMUSCLA) is a sodium channel alpha subunit blocker.

EMA: approved Cardiovascular system (C01) C01BB02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — mexiletine hcl
Class
Cardiovascular system (C01)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

mexiletine hcl (NAMUSCLA) is a sodium channel alpha subunit blocker.

Key facts

INN mexiletine hcl
Brand NAMUSCLA
Mechanism Sodium channel alpha subunit blocker
Target Sodium channel alpha subunit
Therapeutic class Cardiovascular system (C01)
ATC code C01BB02

Mechanism of action

Sodium channel alpha subunit blocker

Primary target: Sodium channel alpha subunit

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. MEX-NDM-301 Phase 3 · Lupin (Europe) · Non-Dystrophic Myotonias (NDM)
  2. MEX-NM-303 Approved · Lupin (Europe) · Myotonic disorders: Nondystrophic myotonias (NDM) or myotoni

Related & competitor drugs

  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. carbamazepine Sodium channel alpha subunit blocker

Frequently asked questions

What is mexiletine hcl?

mexiletine hcl (NAMUSCLA) is a sodium channel alpha subunit blocker.

What is the brand name for mexiletine hcl?

NAMUSCLA is a marketed brand name for mexiletine hcl. Check FDA Drugs@FDA for the current US label holder and prescribing information.